Clinical Trial Update: Tolerability and Immunogenicity of a Single 40-ug Dose of rBV A/B for the Production of BabyBIG® [Phase 2]

View source ↗

Summary

Phase 2 trial update reports tolerability and immunogenicity of a single 40-µg dose of rBV A/B used in the production of BabyBIG.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Botulism

Drugs mentioned

• BabyBIG (botulism immune globulin intravenous)
• rBV A/B (recombinant botulinum neurotoxin type A/B)

Snippet

Sponsor: California Department of Public Health | Conditions: Botulism | Phase 2 | Status: COMPLETED